. Author manuscript; available in PMC: 2017 Jul 1.

Published in final edited form as: Clin Nucl Med. 2016 Jul;41(7):515–521. doi: 10.1097/RLU.0000000000001197

TABLE 2.

Biochemical Findings and Lesion Detectability

	n	Sequential Imaging Approach Positive, n (%)	¹⁸F-Choline Positive, n (%)	⁶⁸Ga-PSMA Positive, n in Choline-Negative Patients (%)
Overall	125	107/125 (85.6%)	93/125 (74.4%)	14/32 (43.8%)
PSA level (ng/mL)
≥0.2–< 1	26	16/26 (61.5%)	12/26 (46.1%)	4/14 (28.6%)
1–2	33	27/33 (81.8%)	22/33 (66.7%)	5/11 (45.5%)
>2	66	64/66 (97.0%)	59/66 (89.4%)	5/7 (71.4%)
PSA doubling time (mo)^*
≤4	34	28/34 (82.4%)	26/34 (76.5%)	2/8 (25.0%)
>4–6	23	22/23 (95.7%)	21/23 (91.3%)	1/2 (50.0%)
>6	67	56/67 (83.6%)	46/67 (68.7%)	10/21 (47.6%)
PSA velocity (ng/mL per year)^*
<1	40	27/40 (67.5%)	21/40 (52.5%)	6/19 (31.5%)
1–< 2	31	28/31 (90.3%)	26/31 (83.9%)	2/5 (40.0%)
2–< 5	26	24/26 (92.3%)	19/26 (73.1%)	5/7 (71.4%)
≥5	27	27/27 (100%)	27/27 (100%)	—

PSA indicates prostate-specific antigen; PSMA, prostate-specific membrane antigen;

PSA kinetics not available in 1 patient;